Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01121770 · ClinicalTrials.gov registry record · Phase 1
"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"
A Phase 1 study of Renal Insufficiency, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT01121770 is a Phase 1 study of Renal Insufficiency that has completed, run by Duke University. The registered enrollment target is 9 participants, below the 101-participant average among 22 other Renal Insufficiency trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01121770, a Phase 1 study of Renal Insufficiency, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine a preventative dose of study drug, Arixtra® for patients with kidney disease. We will measure the blood levels of Arixtra® in patients with kidney disease and develop guidelines for dosing.
Conditions Studied
Interventions
- DRUG fondaparinux sodium injection
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01121770
The ClinicalTrials.gov registry entry for NCT01121770 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101-participant average among 22 other Renal Insufficiency trials with a reported enrollment target (91% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Insufficiency appearing as the primary indexed condition, and to 1 intervention - of which fondaparinux sodium injection is the first listed.
NCT01121770 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01121770 about?
NCT01121770 is a clinical study titled ""Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"". The purpose of this study is to determine a preventative dose of study drug, Arixtra® for patients with kidney disease. We will measure the blood levels of Arixtra® in patients with kidney disease and develop guidelines for dosing.
What is the current status of trial NCT01121770?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2010-05. Estimated completion is 2013-02.
What conditions does trial NCT01121770 study?
This clinical trial studies the following conditions: Renal Insufficiency.
What interventions are being tested in trial NCT01121770?
The interventions under investigation include: fondaparinux sodium injection (DRUG).
Who is sponsoring clinical trial NCT01121770?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01121770 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment
COMPLETED · Phase 1
-
Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects
COMPLETED · Phase 1
-
A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.